A
$171.29+2.09%
as of close, Oct 5, 2026
☾ AH $171.29 +2.09%
Agilent Technologies Inc.Stock · HealthcareS&P 500 Equal Weight 0.2%S&P 500 0.06%Russell 1000 0.05%US Stock Market 0.05%Russell 3000 0.05%MSCI World 0.04%MSCI ACWI 0.04%
A — Agilent Technologies Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDEDEDEDE
60.080.0100.0120.0140.0160.0020.0M$171.29—20162019202120242026
2026-10-05
Price$171.29
MA20$139.01
MA50$134.06
Vol9.4M
Key stats#
Price data
- Price
- $171.29
- YTD price return
- +25.88%
- YTD total return
- +26.64%
- Next earnings
- Nov 23, 2026
- Market cap
- 48.3B
- Enterprise value
- 50.7B
- Shares outstanding
- 281.9M
- 52W low
- $108.35
- 52W high
- $177.05
- From 52W high
- -3.25%
- From 52W low
- +58.09%
- 52W range
- 92%
- Beta
- 1.23
Volume
- Rel volume
- 0.68×
- 30D volume
- 2.6M
- 30D $ vol
- 411.8M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$96K
- Insider net 1Y
- −$313K
Form 4 transactions by trade date, as filed; latest on file 2026-09-04.
Fundamentals
- Sales (ttm)
- 7.4B
- Sales/share
- $26.15
- EPS (ttm)
- $5.08
- FCF (ttm)
- 1.3B
- FCF/share
- $4.49
- Book value/share
- $26.12
- Net margin
- 19.53%
- ROE
- 19.56%
- ROA
- 10.31%
- Debt / equity
- 0.50×
- Current ratio
- 2.05
Growth (CAGR, ttm) · 10Y
- Sales
- +8.61%+1.77%+3.72%+5.98%
- Net income
- +18.05%+8.32%+7.78%+12.37%
- FCF
- +16.46%-3.73%-0.02%+6.33%
- Shares
- -0.55%-1.23%-1.41%-1.39%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +18.98%+9.98%+9.64%+14.15%
- Sales/share
- +9.22%+3.04%+5.21%+7.47%
- FCF/share
- +17.11%-2.53%+1.42%+7.83%
- Book value/share
- +16.25%+11.19%+9.84%+6.91%
- Dividend/share
- +3.37%+4.60%+5.86%+8.57%
- Price
- +21.04%+15.78%+2.28%+13.84%
- Total return
- +21.77%+16.59%+2.98%+14.71%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 33.7×
- P/OI (ttm)
- 29.5×
- Fwd P/E
- 24.8×
- P/S (ttm)
- 6.6×
- P/B (mrq)
- 6.6×
- P/FCF (ttm)
- 38.1×
- EV/EBITDA (fy)
- 26.5×
- EV/Sales (ttm)
- 6.9×
- FCF yield (ttm)
- 2.62%
- Dividend yield (fwd)
- 0.60%
- Dividend yield (ttm)
- 0.59%
- Dividend/share (fwd)
- $1.02
- Buyback yield (realized, 1y)
- 0.55%
- Shareholder yield (realized, 1y)
- 1.43%
- Buyback yield (cash, ttm)
- 0.79%
- Shareholder yield (cash, ttm)
- 1.38%
Vs own 10Y history
- P/E
- 62nd
- P/OI
- 76th
- P/S
- 86th
- P/B
- 67th
- P/FCF
- 84th
Bar = where today’s multiple sits in A’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-05#
1D
+2.09%
5D
-2.24%
1M
+13.54%
3M
+31.07%
YTD
+25.88%
1Y
+20.93%
5Y
+11.93%
Recent filings#
- Sep 88-K · Directors or officers; compensation; Regulation FD disclosure
- Sep 4Insider sale · Dolsten Mikael (Director) sold 634 shares for $96K at $151.38
- Sep 1Report · Quarterly report, Q3 2026 — revenue $1.88B (+8% y/y), net income $362.0M, EPS $1.28
- Aug 26Earnings · Earnings release — EPS $1.62 vs $1.48 est. (+9.5%); revenue $1.88B (+8% y/y) 1.7%
- Jun 258-K · Material definitive agreement; New financial obligation
Financial statements
Open full A financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | -0.54% | +0.02% |
| JNJ | Johnson & Johnson | -8.10% | -1.21% |
| ABBV | AbbVie Inc. | +3.63% | +1.12% |
| MRK | Merck & Co. Inc. | -7.18% | -3.30% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -4.67% | +1.80% |
| TMO | Thermo Fisher Scientific Inc. | +10.26% | +3.35% |
| AMGN | Amgen Inc. | -7.83% | -0.01% |
| GILD | Gilead Sciences Inc. | -4.22% | -0.08% |
